Corona Remedies Ltd (CORONA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Corona Remedies Ltd on NSE and BSE, with an AI summary of each filing.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 04 Nov 2026, 3:43 am
CORONA Remedies Receives ₹4.88 Crore NPPA Demand Notice CORONA Remedies received a Demand Notice on 3rd Nov'26 from the National Pharmaceutical Pricing Authority (NPPA) for ₹4,87,97,160, including interest and penalties. The demand pertains to an alleged violation of Para 15 under the Drugs (Prices Control) Order, 2013 regarding prior price approvals. The company stated it is evaluating the notice to pursue appropriate legal actions and confirmed that the notice will not have any material financial impact on its operations.
Audio Recording of Q2H1FY27 Earnings Conference Call with Analysts / Investors
Audio / Video · 02 Nov 2026, 10:58 pm
Corona Remedies Releases Q2 & H1FY27 Earnings Conference Call Audio Recording Corona Remedies Limited has released the audio recording of its Q2 and H1FY27 earnings conference call held with analysts and investors. The post-earnings call discussed the company's unaudited financial results for the second quarter and half year ended 30th Sep'26. The recording has been made publicly accessible on the company's official website pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation for Analyst / Investor Meet
Intimation · 31 Oct 2026, 11:45 pm
Corona Remedies Schedules Analyst and Investor Meetings in London and UAE Corona Remedies Limited has scheduled meetings with investors and analysts. Company officials will conduct 1x1 and group meetings in London on 4th Nov'26 starting at 09:00 A.M. BST, followed by meetings in the United Arab Emirates (UAE) on 5th Nov'26 and 6th Nov'26 starting at 09:00 A.M. GST. Discussions will strictly focus on publicly available information with no unpublished price-sensitive information (UPSI) involved.
Analyst / Investor Presentation
Investor Presentation · 31 Oct 2026, 2:13 am
CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance CORONA Remedies reported revenue of INR 863.6 Cr (+22.0% YoY), EBITDA of INR 189.1 Cr (+27.5% YoY, margin 21.9%), and PAT of INR 120.4 Cr (+22.2% YoY) for H1 FY27, with annualized ROCE at 49.8% and ROE at 32.9%. Q2 FY27 revenue grew 22.2% YoY to INR 441.2 Cr. Chronic and sub-chronic therapies contributed ~72.1% of H1 FY27 revenue, while India accounted for 97.1%. The company secured ANVISA GMP certification for its Bhayla OSD and hormone facility in Oct'26.
Press Release on Financial Results for second quarter and half year ended on September 30, 2026
Press Release · 31 Oct 2026, 12:16 am
CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth CORONA Remedies reported 22.2% YoY revenue growth to ₹441.2 Cr in Q2FY27, outpacing IPM growth by 1.9x for MAT Sep'26. EBITDA rose 22.3% YoY to ₹96.0 Cr with stable margins at 21.7%, while PAT increased 15.3% YoY to ₹60.3 Cr, impacted by higher depreciation and amortization from newly commissioned facilities and brand acquisitions. Chronic and semi-chronic therapies contributed 71.2% to revenue. Additionally, the company secured Brazil's ANVISA GMP certification for its Bhayla facility covering oral solids and women's hormone production lines.
Unaudited Financial Results along with the Limited Review Reports for the second quarter and half year ended September 30, 2026
Financial Result · 31 Oct 2026, 12:12 am
CORONA Remedies Reports Q2 FY27 Consolidated Financial Results CORONA Remedies reported a 22.16% YoY increase in consolidated revenue from operations to Rs 441.17 crore for the quarter ended 30th Sep'26, compared to Rs 361.13 crore in the corresponding period last year. Consolidated net profit rose 15.27% YoY to Rs 60.31 crore from Rs 52.32 crore, delivering a basic and diluted EPS of Rs 9.86 versus Rs 8.55. For H1 ended 30th Sep'26, consolidated revenue grew 22.03% YoY to Rs 863.60 crore, while net profit advanced 22.23% YoY to Rs 120.42 crore.
CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 31 Oct 2026, 12:05 am
Outcome of Board Meeting
Outcome · 30 Oct 2026, 11:58 pm
Corona Remedies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 441 (+22.2% YoY | +4.4% QoQ) ■ EBITDA: 96.0 (+22.3% YoY | +3.0% QoQ) ■ EBITDA Margin (%): 21.7 (+2 bps YoY | -30 bps QoQ) ■ PAT: 60.3 (+15.3% YoY | +0.3% QoQ) ■ EPS (INR): 9.86 (+15.3% YoY | +0.3% QoQ)
Press Release on GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil
Press Release · 23 Oct 2026, 12:12 am
CORONA Remedies Secures ANVISA GMP Certification for Bhayla Facility CORONA Remedies received Good Manufacturing Practice (GMP) certification from Brazil's ANVISA on 22nd Oct'26 for its Bhayla, Ahmedabad facility, covering Oral Solid Dosage and Women's Hormone production lines. This marks the company's third major global GMP clearance, complementing existing EU-GMP and EAEU-GMP accreditations. While India remains its core market driving over 96% of revenue, the approval facilitates strategic expansion into Brazil's estimated USD 44 billion pharmaceutical market.
Intimation regarding receipt of GMP Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil for OSD manufacturing facility and Hormone manufacturing facility of ....
Others (Uncategorized) · 22 Oct 2026, 4:33 pm
CORONA Remedies Secures ANVISA Brazil GMP Certification for Ahmedabad Facilities CORONA Remedies has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s health regulatory agency, ANVISA, on 22nd Oct'26. The approval covers both its Oral Solid Dosage (OSD) manufacturing facility and its Hormone manufacturing facility located at Bhayla, Ahmedabad. This key regulatory clearance validates international quality compliance and enhances the company's export potential into Latin American pharmaceutical markets.
Intimation for Schedule of Analyst / Investor Conference
Intimation · 02 Nov 2026, 11:30 am
CORONA Remedies Schedules Q2 FY27 Earnings Conference Call for 2nd Nov'26 CORONA Remedies Limited will host its Q2 FY27 post-earnings conference call on 2nd Nov'26 at 11:30 AM IST to discuss financial results for the quarter and half-year ended 30th Sep'26. The call will be hosted by Ambit Capital and attended by top management, including Managing Director & CEO Nirav Mehta, Joint Managing Director Ankur Mehta, and Chief Financial Officer Bhavin Bhagat. Primary access numbers are +91 22 6280 1148 and +91 22 7115 8049, alongside international toll-free options.
CORONA REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 30 Oct 2026, 5:30 am
CORONA Remedies Board to Consider Q2 and H1 Results on 30th Oct'26 CORONA Remedies Limited has scheduled a Board of Directors meeting on 30th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed until 1st Nov'26 pursuant to insider trading regulations.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
Credit Rating
Others (Uncategorized) · 01 Oct 2026, 12:46 am
CARE Upgrades Corona Remedies Short-Term Facilities to CARE A1+ CARE Ratings has revised and upgraded Corona Remedies Limited's ratings following a review of FY26 audited and Q1FY27 unaudited performance. The company’s long-term/short-term bank facilities of ₹70.00 crore were upgraded to CARE A+; Stable / CARE A1+ from CARE A+; Stable / CARE A1. Concurrently, ratings for long-term bank facilities of ₹7.00 crore (reduced from ₹25.00 crore) were reaffirmed at CARE A+; Stable. Total rated bank facilities stand at ₹77.00 crore.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd, Sage Investment Trust ....
Acquisition/ Disposal of Shares · 19 Sept 2026, 9:12 pm
Sepia Investments, Sage Investment Trust, and Anchor Partners Trim Stake in Corona Remedies Sepia Investments Limited, Sage Investment Trust, and Anchor Partners offloaded equity stakes in Corona Remedies Limited via open market sales on NSE on 10th Sep'26. Sepia Investments sold 2,485,476 shares (4.06%), reducing its holding from 12.68% to 8.62% (5,270,310 shares). Sage Investment Trust disposed of 51,641 shares (0.08%), paring its stake from 0.26% to 0.18% (109,759 shares). Anchor Partners divested 92,763 shares (0.15%), lowering its holding from 0.47% to 0.32% (197,229 shares). Total company equity capital remains unchanged at 61,160,088 shares (INR 611.60mn).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd, Sage Investment Trust ....
Acquisition/ Disposal of Shares · 19 Sept 2026, 8:44 pm
Sepia Investments, Sage Investment Trust, and Anchor Partners Trim Stake in Corona Remedies On 10th Sep'26, Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold an aggregate 2,629,880 equity shares (4.29% stake) of Corona Remedies Limited via open market transactions on the NSE. Individually, Sepia Investments offloaded 2,485,476 shares (4.06%), reducing its stake from 12.68% to 8.62%. Sage Investment Trust sold 51,641 shares (0.08%), trimming holding from 0.26% to 0.18%, while Anchor Partners divested 92,763 shares (0.15%), cutting its stake from 0.47% to 0.32%. Total paid-up equity capital remains unchanged at INR 611.60 mn.
Intimation of participation in Analyst / Investor meet
Intimation · 18 Sept 2026, 8:26 pm
CORONA Remedies Schedules JP Morgan-Organized Group Investor Meeting CORONA Remedies Limited announced that company officials will participate in an analyst and investor group meeting organized by JP Morgan on 23rd Sep'26 at 2:00 PM in Ahmedabad. The company confirmed that interactions will rely solely on publicly available information, with no unpublished price-sensitive information (UPSI) to be discussed during the scheduled interaction.
Reply to Clarification
Others (Uncategorized) · 10 Sept 2026, 5:38 pm
CORONA Remedies Clarifies Share Trading Volume Increase is Market-Driven CORONA Remedies Limited clarified to BSE on 10th Sep'26 that recent increases in its share trading volume are purely market-driven. The company confirmed full compliance with SEBI Listing Regulations, noting that all material events impacting operations or performance have been disclosed promptly. Additionally, management stated there is no undisclosed price-sensitive information, pending announcements, or impending corporate actions that require reporting to the exchange at this stage.
The Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Others (Uncategorized) · 10 Sept 2026, 4:38 pm
Intimation of participation in Analyst / Investor Conference
Intimation · 20 Aug 2026, 10:48 pm
Corona Remedies To Hold In-Person Group Investor Conference Corona Remedies Limited will participate in an in-person group investor conference in Ahmedabad. The meeting, organized by Phillip Capital PCG, is scheduled for 26th Aug'26, starting at 11:00 AM IST. Discussions will be based on publicly available information, with no unpublished price-sensitive information (UPSI) to be shared. The company's BSE scrip code is 544644, and its NSE symbol is CORONA.
Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026
Transcript · 10 Aug 2026, 11:24 pm
Intimation for Schedule of Analysts / Investor Conference
Intimation · 10 Aug 2026, 4:50 pm
Corona Remedies Schedules Investor Meetings in August 2026 Corona Remedies Limited will participate in two upcoming investor conferences in Mumbai. Company officials will attend the Emkay Global Investor Conference on 13 Aug'26 and the Equirus Investor Conference on 14 Aug'26. Both events will commence at 10:00 AM IST and will feature in-person group and one-on-one meetings. Discussions will be limited to publicly available information, with no disclosure of unpublished price-sensitive information. The schedule is subject to change based on exigencies.
Audio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors
Audio / Video · 03 Aug 2026, 9:50 pm
Corona Remedies Makes Q1 FY27 Earnings Call Recording Available Corona Remedies announced on Aug 03, '26, that the audio recording of its Q1 FY27 earnings conference call is now accessible on the company's website. The call, held with analysts and investors, covered the unaudited financial results for the quarter ending Jun 30, '26. This follows the company's initial results disclosure on Jul 22, '26, and complies with SEBI's listing regulations. The recording can be found at the provided URL on their investor relations page.
Analyst/Investor presentation
Investor Presentation · 01 Aug 2026, 1:04 am
Corona Remedies Q1 FY27: Strong Revenue Growth and Margin Expansion For Q1 FY27, Corona Remedies reported strong YoY growth with revenue at INR 422.4 Cr (+21.9%), EBITDA at INR 93.1 Cr (+33.5%), and PAT at INR 60.1 Cr (+30.1%). EBITDA margin expanded by 190 bps to 22.0%, and PAT margin grew by 90 bps to 14.2%. Chronic and sub-chronic therapies contributed 73.4% to Q1 revenue. The company improved its IPM rank to 26th for MAT Jun-26 and inaugurated a new EU-GMP-certified Hormone facility in Jun'26, strengthening its women's healthcare segment.